Skinvisible Expands Its Patent Portfolio with Comprehensive Acne Patent Adapalene, Retinoic Acid, Clindamycin and OTC Actives Now with IP Protection

LAS VEGAS, NV / ACCESSWIRE / September 29, 2015 / Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) a pharmaceutical research and development company with its proprietary skin delivery technology Invisicare(R), today announced that it has expanded its patent portfolio with a new patent granted by the United States Patent and Trademark Office entitled, “ACNE TREATMENT COMPOSITION AND METHODS FOR USING.”

“This patent is an important component of Skinvisible’s comprehensive intellectual property portfolio which includes sixteen patents that provide protection in the US and major international markets up to the year 2030. The granting of this patent recognizes the unique qualities of our Invisicare delivery technology. With the acne market generating over $5 billion in the U.S. last year, this new patent further enhances the value of our pipeline of products,” said Mr. Terry Howlett, President. “We are actively seeking a partner to license and advance the clinical development of our acne formulations and other prescription dermatology products.”

All Skinvisible formulations are protected by its Invisicare patents. Invisicare is a polymer delivery system with a unique mode of delivery. It is a high performance technology that improves how products are delivered to the skin. It improves the release of actives, the binding of the product, efficacy, safety and consumer satisfaction, allowing for a potential non-inferiority claim using a lower concentration of the active as compared to the market leaders. The Invisicare pipeline includes acne (adapalene, retinoic acid, and clindamycin), actinic keratosis (imiquimod), anti-fungals (naftifine, terbinafine) plus others including an orphan drug candidate.

Demand for a patent protected pipeline of dermatology products is growing rapidly as the global medical dermatology market continues to expand and new molecules are not available. Companies are seeking products that are cost-effective and have patent protection to maximize exclusivity. Many companies prefer 505(b)(2) NDA approvals from the FDA due to lower costs and shorter approval times. A 505(b)(2) is a drug approval for a product which contains an active similar to a product already approved; eliminating repetition of some / all studies. This results in a shorter, less costly drug development process which allows the product to go to market quicker and at a lower cost. Additionally, 505(b)(2) products may receive 3 to 7 years of market exclusivity in addition to the Invisicare patent protection.

Skinvisible Inc. is a science-based research and development company with a patented skin delivery technology Invisicare(R), the foundation to every prescription (Rx), over-the-counter (OTC) and cosmeceutical product developed by the Company. Skinvisible continues to build its worldwide patent portfolio while seeking licensees for its prescription line of dermatology focused products. Through its wholly-owned subsidiary Kintari it markets cosmeceutical products and some popular OTC products such as sunscreens. The Company has sixteen patents worldwide and a portfolio of over forty products ready to be licensed or introduced to the marketplace.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. In addition, Skinvisible’s wholly-owned subsidiary Kintari will commercialize its cosmeceutical and OTC product line globally through independent distributors. www.skinvisible.com, www.invisicare.com, www.kintari.com

Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30th, 2015).

Contact:

Doreen McMorran, Skinvisible Inc.
Email: info@skinvisible.com

SOURCE: Skinvisible Inc.

ReleaseID: 432281